IL4 and psoriasis: Therefore, the authors believe that blocking the Th2 response by targeting the IL-4 signaling pathway may lead to Th1/Th17 phenotypic transition, resulting in an inflammatory cytokine cascade, ultimately showing psoriasis skin lesions.